Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPR Regimen in Elderly Treatment-naive DLBCL
NCT05940064Phase 2Completed
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, polatuzumab vedotin, rituximab in diffuse large B-cell lymphoma (DLBCL). Started Dec 2023; status: completed.
02
Drugs
zanubrutinibpolatuzumab vedotinrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05940064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940064.